AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.